DEEP BRAIN STIMULATION DEVICES MARKET ANALYSIS

Deep Brain Stimulation Devices Market Size and Forecast – 2024 to 2031

The Global Deep Brain Stimulation Devices Market is estimated to be valued at USD 1.50 billion in 2024 and is expected to reach USD 3.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.5% from 2024 to 2031.

Key Takeaways of the Deep Brain Stimulation Devices Market:

• By Product Type, Single-channel DBS Devices segment contributes the highest share of the market with 52.1% in 2024.
• By Application, Epilepsy contributes the highest share of the market with 36.2% in 2024.
• By End User, Hospitals contributes the highest share of the market with 40.1% in 2024.
• North America to top the global market with 38.4% share, followed by Asia Pacific with 27.7% share in 2024.

Market Overview

The deep brain stimulation devices market is witnessing positive trends with major players continuously innovating and launching new products with enhanced features. Technological advancements have allowed improved targeting abilities and battery lives in these devices. Further miniaturization of deep brain stimulators along with the integration of biosensors is expected to make the treatment safer and more effective. This is anticipated to boost the adoption of deep brain stimulation especially for neurological conditions.

Segmental Insights

To learn more about this report, Request sample copy

Product Type Insights - Affordability and Effectiveness Drive Adoption of Single-channel DBS Devices

In terms of Product Type, Single-channel DBS Devices segment is estimated to contribute the highest market share with 52.1% in 2024, owing to their affordable price point and proven effectiveness. As hospitals, clinics, and other healthcare providers aim to treat more patients while managing costs, single-channel devices have emerged as an attractive option. Their simpler, single lead design allows for lower production expenses which are passed on to customers. This has made deep brain stimulation therapy accessible to a wider population grappling with neurological conditions. Doctors also favor single-channel DBS given the solid clinical evidence for its benefits. Numerous peer-reviewed studies over decades confirm that stimulation of targeted brain areas via a single electrode can significantly reduce symptoms for neurological disorders like Parkinson's disease and essential tremor.

Application Insights - Expanding Use of Deep Brain Stimulation Device in Pain Management

In terms of Application, Pain Management segment is estimated to contribute the highest market share of 36.2% in 2024. Though Deep Brain Stimulation was first approved to treat movement disorders like Parkinson's disease, its use has rapidly expanded into new therapeutic areas. Chronic pain affects millions and poses a major global health challenge due to limited treatment options and side effects of medication. As a result, neurological centers have actively evaluated deep brain stimulation as an alternative approach for pain syndromes. Studies show DBS can significantly reduce intensity and interference of various types of pain including those related to trauma, arthritis, and neurological damage.

End User Insights- Hospitals Lead as the Major End User Due to Infrastructure and Expertise

In terms of End User, Hospitals segment is estimated to contribute the highest market share of 40.1% in 2024, owing to their advanced infrastructure and multidisciplinary teams. Deep brain stimulation requires sophisticated operating rooms, specialized imaging equipment, and coordinated care by neurosurgeons, neurologists, nurses, and technicians. It also demands comprehensive follow-up support for optimal therapeutic effect. While some clinics have capability for DBS, hospitals are best equipped to cater to the entire integrated process from patient selection to long-term management.

Regional Insights

To learn more about this report, Request sample copy

North America Deep Brain Stimulation Devices Market Insights

North America dominates the deep brain stimulation devices market with an estimated share of 38.4% in 2024. This can be attributed to factors such as the presence of major industry players, availability of reimbursements, growing aging population susceptible to neurological disorders, and technical advancements. Companies like Medtronic, Boston Scientific, and Abbott have established a significant presence in the region and continue to invest in developing innovative technologies.

Asia Pacific Deep Brain Stimulation Devices Market Insights

The Asia Pacific region exhibits the fastest growth with an estimated share of 27.7% in 2024 and is expected to rise at a considerable rate over the forecast period. This can be credited to the improving healthcare infrastructure, increasing medical tourism, growing prevalence of neurological disorders due to changing lifestyle habits, rising disposable incomes, and supportive government policies focused on strengthening the medical devices industry across countries in the region.

Deep Brain Stimulation Devices Market Outlook for Key Countries

U.S. Deep Brain Stimulation Devices Market Insights

The U.S. deep brain stimulation devices market is anticipated to lead globally during the forecast period, driven by the rising prevalence of neurological disorders such as Parkinson's disease, dystonia, and essential tremors, along with an increasing number of clinical trials targeting psychiatric disorders. Technological advancements in DBS, including improved lead designs, implantable pulse generators, and remote monitoring capabilities, are enhancing the therapy's effectiveness and safety in the U.S. According to a 2022 Parkinson’s Foundation study, approximately one million individuals in the U.S. are living with Parkinson's disease, a number projected to rise to nearly 1.2 million by 2030. However, the high cost of DBS therapy, coupled with the complexity and potential risks associated with DBS implantation, is expected to pose challenges to the growth of the deep brain stimulation devices, deep brain stimulation devices market in the U.S.

Japan Deep Brain Stimulation Devices Market Insights

The deep brain stimulation devices market in Japan is experiencing substantial growth, fueled by the rising demand for innovative treatments for neurological disorders. DBS is approved in Japan for treating Parkinson's disease, and the market has shown steady expansion in recent years. The increasing prevalence of neurological disorders, driven by the country's aging population, has significantly boosted the demand for DBS devices. According to data published by the WHO in 2020, Parkinson's disease accounted for approximately 14,007 deaths in Japan, representing 1.27% of total deaths. Additionally, government-led initiatives to support the development and adoption of DBS technologies are expected to further drive the market growth during the forecast period.

Germany Deep Brain Stimulation Devices Market Insights

Germany's robust healthcare system supports the demand for deep brain stimulation devices, with significant investments in medical technology. Boston Scientific Corporation has received Ce Mark and launched the fourth-generation vercise genus deep brain stimulation (DBS) system in Germany. The system, featuring full-body MRI compatibility and Bluetooth capabilities, is designed to treat Parkinson's disease, essential tremor, and dystonia through precise brain stimulation for optimal symptom relief.

U.K. Deep Brain Stimulation Devices Market Insights

The U.K.'s National Health Service (NHS) has been integrating advanced deep brain stimulation technologies to address neurological disorders. In November 2022, the NHS adopted new DBS systems with enhanced MRI compatibility, improving treatment accessibility and patient safety. These developments highlight the global expansion and acceptance of DBS devices, driven by technological innovations and supportive healthcare policies.

Market Players, Key Devlopment, and Competitive Intelligence

Get actionable strategies to beat competition: Request sample copy

Top Strategies Followed by Global Deep Brain Stimulation Devices Market Players

• Established Players: Leading players in the global deep brain stimulation devices market heavily invest in research and development to drive product innovation. Medtronic, for instance, spends over US$ 2 billion annually on R&D with the aim of developing cutting-edge neurostimulation technologies. Boston Scientific expands its R&D capabilities through acquisitions and partnerships to introduce advanced DBS systems for difficult-to-treat neurological disorders.
• Mid-Level Players: These companies focus on delivering quality, budget-friendly products targeting price-sensitive consumers. For example, Aleva Neurotherapeutics offers innovative DBS systems designed to be cost-effective, catering to a broader patient demographic. Partnerships aimed at boosting technology and production capabilities are common. NeuroOne Medical Technologies has collaborated with Zimmer Biomet to enhance its electrode technology, aiming to improve patient outcomes and expand its market presence.
• Small-Scale Players: Smaller companies often target niche markets with unique features. For instance, InBrain Neuroelectronics is developing graphene-based brain implants, aiming to provide more effective and less invasive DBS solutions. Collaborations with local manufacturers help gain market entry. For example, Beijing Pins Medical has partnered with local healthcare providers to introduce its DBS systems into the Chinese market, enhancing visibility and adoption.

Emerging Startups - Deep Brain Stimulation Devices Industry Ecosystem

• Innovative Technologies: Several startups are actively working on next-gen DBS technologies. Kernel, a neurotech startup, is developing a neural implant and companion app to non-invasively treat neurological disorders. Another example is NeuroPace, which created the RNS System - the first FDA-approved brain stimulator for epilepsy.
• Sustainable Solutions: Startups like Anthropic focus on designing AI-powered brain implants that can be recycled and remanufactured sustainably. Greensboro, Alabama-based MyndYou is creating biodegradable, plant-based materials for brain implants reducing health and environmental risks.
• Some startups are targeting niche, underserved segments in the market. For example, Flow Neuroscience focuses on treating psychiatric conditions such as OCD and PTSD through localized brain stimulation. The company collaborates with research institutions to validate its innovative, non-invasive techniques. Similarly, the early-stage startup Synchron specializes in restoring motor functions lost after a stroke by utilizing spinal cord stimulation, developed in partnership with leading healthcare organizations.

Key Developments:

• In September 2024, Abbott, a global healthcare leader known for its innovative medical devices, launched the TRANSCEND study, a pivotal clinical trial to evaluate the efficacy of its DBS system in treating treatment-resistant depression (TRD), a severe form of major depressive disorder
• In September 2024, Medtronic, a pioneer in medical technology, released the trial design and preliminary findings of the ADAPT-PD trial, which focuses on the use of an adaptive DBS algorithm to deliver personalized therapy for Parkinson's disease
• In January 2024, Abbott received the U.S. FDA approval for its Liberta RC DBS system, the world’s smallest rechargeable DBS device. This innovative system features remote programming capabilities and is designed to improve the quality of life for people living with movement disorders.
• In January 2024, Medtronic gained the U.S. FDA approval for its Percept RC Deep Brain Stimulation (DBS) system. This rechargeable neurostimulator is the latest addition to the Percept family, which includes SenSight directional leads and BrainSense technology for advanced neurological care.
• In January 2021, Boston Scientific, a leading medical device company specializing in DBS systems, received the U.S. FDA approval for its fourth-generation Vercise Genus DBS System. The portfolio includes Bluetooth-enabled, rechargeable and non-rechargeable implantable pulse generators compatible with Cartesia Directional Leads, designed for optimized symptom relief and approved for conditional use in MRI environments.

Market Report Scope

Market Dynamics

Discover market dynamics shaping the industry: Request sample copy

Deep Brain Stimulation Devices Market Growth Factors - Increasing prevalence of neurological disorders

Neurological disorders like Parkinson's, epilepsy, and depression are rising in prevalence globally. Parkinson's, a common movement disorder, affects millions, with cases expected to double in 25 years due to aging populations. Deep brain stimulation (DBS) is an effective treatment for advanced Parkinson's, improving symptoms like tremors and rigidity. Similarly, epilepsy cases are increasing, especially in developing nations. DBS helps manage medication-resistant epilepsy, reducing seizure frequency in treatment-refractory patients. For instance, according to key facts published by the WHO in February 2023, around 50 million people globally are affected by epilepsy, making it one of the most prevalent neurological diseases. Additionally, approximately 80% of those with epilepsy reside in low- and middle-income countries.

Deep Brain Stimulation Devices Market Challenge - High cost of DBS devices

One of the key challenges faced by the global deep brain stimulation devices market is the high cost associated with DBS devices. Deep brain stimulation is considered as one of the most expensive neurosurgical procedures owing to the high price of deep brain stimulation devices. On an average, the total cost of DBS surgery ranges between US$ 50,000 and US$ 100,000 in the U.S. alone. The significant cost burden includes the price of implantable pulse generators (around US$ 25,000) and electrodes (around US$ 10,000) used during the surgery. Moreover, additional costs occur for programming equipment, surgical fees, and overhead operating costs of clinics and hospitals. The out-of-pocket costs for patients without proper insurance cover can deter their adoption of DBS therapy. Device manufacturers face pricing pressures to make the therapy affordable for more patients globally. However, bringing down the costs substantially without comprising on device effectiveness and longevity remains a challenge.

Deep Brain Stimulation Devices Market Opportunity - Growing Demand for Minimally Invasive Surgical Procedures

One of the key opportunities for the global deep brain stimulation devices market is the growing demand for minimally invasive surgical procedures. Minimally invasive techniques offer various advantages over traditional open surgeries such as lesser pain, fewer complications, shorter hospital stay, and quicker recovery time. In case of DBS, the use of microelectrodes and implantation of thin implantable pulse generators through small incisions results in reduced surgical trauma for patients. This has increased the acceptance of DBS therapy for the treatment of neurological disorders. With continued technological advancements, manufacturers are able to design DBS devices which are smaller in size, less invasive to implant and have enhanced functionalities.

Analyst Opinion (Expert Opinion)

• The global deep brain stimulation devices market has potential for strong growth over the next decade. North America currently dominates due to supportive reimbursement policies and higher acceptance of neuromodulation therapies. However, Asia Pacific region is expected to demonstrate the fastest adoption of DBS devices due to rising geriatric population and increasing healthcare expenditure.
• Key drivers fueling the market expansion are the growing prevalence of neurological disorders such as Parkinson's disease, essential tremors, and dystonia along with the rising number of clinical trials for the evaluation of new therapeutic applications of deep brain stimulation.
• High cost of devices, complex surgical procedures involving DBS implantation, and lack of skilled neurosurgeons in emerging nations are some challenges hampering the faster adoption of these devices globally. Ongoing advancements in design of rechargeable devices to reduce frequent replacement surgeries along with the miniaturization of electrodes to target multiple brain regions are widening therapeutic applications and boosting patient outcomes.
• Leading companies are focusing on partnerships with healthcare providers to create awareness regarding advantages of DBS therapy. Further, continued government support in the form of regulatory approvals and reimbursement will positively influence the market revenues.

Market Segmentation

•  Product Type Insights (Revenue, USD Bn, 2019 - 2031)
• • Single-channel DBS Devices
  • Dual-channel DBS Devices
•  Application Insights (Revenue, USD Bn, 2019 - 2031)
• • Epilepsy
  • Pain Management
  • Essential Tremor
  • Obsessive Compulsive Disorder (OCD)
  • Parkinson’s Disease
  • Depression
  • Dystonia
  • Others
•  End User Insights (Revenue, USD Bn, 2019 - 2031)
• • Hospitals
  • Neurology Clinics
  • Ambulatory Surgical Centers
  • Research Centers
  • Others
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Abbott
  • Medtronic
  • Boston Scientific Corporation
  • Neuropace Inc.
  • LivaNova Plc
  • Renishaw Plc
  • Aleva Neurotherapeutics S.A.
  • Beijing Pinchi Medical Equipment Co. Ltd
  • Nexstim
  • Jude Medical (now part of Abbott)
  • Cyberonics (now part of LivaNova)
  • EBR Systems
  • IntraPace
  • Nevro Corp
  • Stimwave Technologies